Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
<h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal flu...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0257372 |
| _version_ | 1818403952619683840 |
|---|---|
| author | Michael Bartl Mohammed Dakna Douglas Galasko Samantha J Hutten Tatiana Foroud Marian Quan Kenneth Marek Andrew Siderowf Jonas Franz Claudia Trenkwalder Brit Mollenhauer Parkinson’s Progression Markers Initiative |
| author_facet | Michael Bartl Mohammed Dakna Douglas Galasko Samantha J Hutten Tatiana Foroud Marian Quan Kenneth Marek Andrew Siderowf Jonas Franz Claudia Trenkwalder Brit Mollenhauer Parkinson’s Progression Markers Initiative |
| author_sort | Michael Bartl |
| collection | DOAJ |
| description | <h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal fluid (CSF) samples from PPMI (252 PD, 115 healthy controls, HC) were analyzed at six timepoints (baseline, 6, 12, 24, 36, and 48 months follow-up) using Elecsys® electrochemiluminescence immunoassays to quantify neurofilament light chain (NfL), soluble TREM2 receptor (sTREM2), chitinase-3-like protein 1 (YKL40), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), S100, and total α-synuclein (αSyn).<h4>Results</h4>αSyn was significantly lower in PD (mean 103 pg/ml vs. HC: 127 pg/ml, p<0.01; area under the curve [AUC]: 0.64), while all other biomarkers were not significantly different (AUC NfL: 0.49, sTREM2: 0.54, YKL40: 0.57, GFAP: 0.55, IL-6: 0.53, S100: 0.54, p>0.05) and none showed a significant difference longitudinally. We found significantly higher levels of all these markers between PD patients who developed cognitive decline during follow-up, except for αSyn and IL-6.<h4>Conclusion</h4>Except for αSyn, the additional biomarkers did not differentiate PD and HC, and none showed longitudinal differences, but most markers predict cognitive decline in PD during follow-up. |
| first_indexed | 2024-12-14T08:32:26Z |
| format | Article |
| id | doaj.art-2dd6276ca17c4e6e850a0ed593e32cff |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T08:32:26Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-2dd6276ca17c4e6e850a0ed593e32cff2022-12-21T23:09:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011610e025737210.1371/journal.pone.0257372Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.Michael BartlMohammed DaknaDouglas GalaskoSamantha J HuttenTatiana ForoudMarian QuanKenneth MarekAndrew SiderowfJonas FranzClaudia TrenkwalderBrit MollenhauerParkinson’s Progression Markers Initiative<h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal fluid (CSF) samples from PPMI (252 PD, 115 healthy controls, HC) were analyzed at six timepoints (baseline, 6, 12, 24, 36, and 48 months follow-up) using Elecsys® electrochemiluminescence immunoassays to quantify neurofilament light chain (NfL), soluble TREM2 receptor (sTREM2), chitinase-3-like protein 1 (YKL40), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), S100, and total α-synuclein (αSyn).<h4>Results</h4>αSyn was significantly lower in PD (mean 103 pg/ml vs. HC: 127 pg/ml, p<0.01; area under the curve [AUC]: 0.64), while all other biomarkers were not significantly different (AUC NfL: 0.49, sTREM2: 0.54, YKL40: 0.57, GFAP: 0.55, IL-6: 0.53, S100: 0.54, p>0.05) and none showed a significant difference longitudinally. We found significantly higher levels of all these markers between PD patients who developed cognitive decline during follow-up, except for αSyn and IL-6.<h4>Conclusion</h4>Except for αSyn, the additional biomarkers did not differentiate PD and HC, and none showed longitudinal differences, but most markers predict cognitive decline in PD during follow-up.https://doi.org/10.1371/journal.pone.0257372 |
| spellingShingle | Michael Bartl Mohammed Dakna Douglas Galasko Samantha J Hutten Tatiana Foroud Marian Quan Kenneth Marek Andrew Siderowf Jonas Franz Claudia Trenkwalder Brit Mollenhauer Parkinson’s Progression Markers Initiative Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. PLoS ONE |
| title | Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. |
| title_full | Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. |
| title_fullStr | Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. |
| title_full_unstemmed | Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. |
| title_short | Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. |
| title_sort | biomarkers of neurodegeneration and glial activation validated in alzheimer s disease assessed in longitudinal cerebrospinal fluid samples of parkinson s disease |
| url | https://doi.org/10.1371/journal.pone.0257372 |
| work_keys_str_mv | AT michaelbartl biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT mohammeddakna biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT douglasgalasko biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT samanthajhutten biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT tatianaforoud biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT marianquan biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT kennethmarek biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT andrewsiderowf biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT jonasfranz biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT claudiatrenkwalder biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT britmollenhauer biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT parkinsonsprogressionmarkersinitiative biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease |